UroGen Pharma Ltd. (URGN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

UroGen said 1Q ZUSDURI revenue reached about $30 million, more than 100% sequential growth, with the company noting the launch inflected after securing a permanent J-code. Management said February doses already surpassed JELMYTO and that penetration is improving across top accounts. The tone was constructive on launch momentum and reimbursement progress, which should support near-term investor sentiment.

Analysis

The key read-through is that URGN’s launch is no longer a clinical adoption story; it has become a reimbursement execution story, which materially lowers near-term volatility in demand. Once a permanent billing code removes physician office uncertainty, the funnel can re-rate quickly because the bottleneck shifts from “willingness to use” to “operational capacity to absorb new patients,” which tends to be a much faster slope for specialty drugs. That inflection often creates a multi-quarter compounding effect rather than a one-time step-up, especially when early prescribers begin cascading into adjacent practices.

Second-order, this is bad news for incumbent therapy share and for any alternative treatment pathway that relies on easier administrative friction rather than superior efficacy. If reimbursement is now the gating item, competitors with weaker evidence but simpler economics lose their main advantage; the next battlefield becomes physician habit formation and payer policy, where URGN can potentially defend share better than the launch skeptics expect. The biggest hidden beneficiary may be the specialty pharmacy / buy-and-bill infrastructure around the product, as faster throughput can improve stocking discipline and lower abandonment rates.

The main risk is that the current acceleration is front-loaded: early adopters and pent-up demand can overstate the sustainable run-rate for 1-2 quarters before normalization. The market may also be extrapolating too aggressively from account penetration into full prescription persistence; if repeat dosing or patient conversion underperforms, the growth curve could flatten faster than consensus models assume. Watch for payer mix drift, office-level inventory dynamics, and any evidence that the post-code surge is mostly catch-up rather than net-new demand.

Key Decisions for Investors

• Stay long URGN for the next 1-2 quarters on launch acceleration; use pullbacks toward post-earnings support to add, targeting a 20-30% upside re-rate if the run-rate sustains through the next two prints.
• If long URGN, protect with near-dated put spreads rather than outright sales; the main downside risk is a sharp air-pocket if the market concludes the January/February inflection was mostly pent-up demand.
• Pair trade: long URGN / short a basket of lower-friction urology incumbents or reimbursement-sensitive specialty launch names over 3-6 months; the relative winner is the asset with the cleanest billing economics, not necessarily the strongest headline growth.
• Watch for a catalyst trade into the next quarterly update: if account penetration and refill behavior confirm durability, add aggressively; if the company only reiterates dose growth without persistence metrics, fade the move.
• For more tactical exposure, buy call spreads 2-4 months out to express continued launch momentum while capping premium at risk; the setup favors convexity because reimbursement-driven inflections often persist longer than the market initially prices.